Roche moves deeper into Merck territory with Tecentriq/chemo OK in frontline NSCLC
Roche has nailed down the FDA approval it needs to catch up with Merck in frontline non-squamous non-small cell lung cancer, positioning Tecentriq for a broader swath of patients.
The latest OK covers the use of the PD-L1 drug in combination with a chemotherapy regimen comprising Abraxane and carboplatin in NSCLC patients whose cancer has metastasized and doesn’t carry EGFR or ALK genomic tumor aberrations.
It’s a similar label to Merck’s PD-1 star Keytruda, which was approved in conjunction with a different type of chemo for frontline treatment last August.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,300+ biopharma pros reading Endpoints daily — and it's free.